Mechanism of neutrophil recruitment induced by IL-8 in chronic sinusitis

Suzuki, Hideaki; Takahashi, Yuichi; Wataya, Hideya; Ikeda, Katsuhisa; Nakabayashi, Seiichiro; Shimomura, Akira; Takasaka, Tomonori

doi:10.1016/s0091-6749(96)70100-8

Cited by 91 publications

(85 citation statements)

References 69 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[23][24][25][26] IL-8 is an inflammatory cytokine with a strong effect on neutrophil activation and chemotaxis. 27,28 Early evidence for the involvement of this chemokine in allergic inflammation was obtained from a study that demonstrated that cultured bronchial epithelial cells derived from asthmatic subjects released IL-8 into culture supernatant.…”

Section: Discussionmentioning

confidence: 99%

Enhanced Neutrophil Chemotactic Activity After Bronchial Challenge in Subjects with Grain Dust-Induced Asthma

Park

Jung

1998

Annals of Allergy, Asthma & Immunology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Enhanced Neutrophil Chemotactic Activity After Bronchial Challenge in Subjects with Grain Dust-Induced Asthma

Park

Jung

1998

Annals of Allergy, Asthma & Immunology

View full text Add to dashboard Cite

“…Long-term macrolide therapy has been shown to improve symptoms, shrink the size of nasal polyps, and decrease the levels of pro-inflammatory cytokines in patients with CRS, although mainly in small, open-label studies [89][90][91][92]. As with other diseases, the mechanisms behind this beneficial effect are unclear and may relate to the ability of macrolides to inhibit the local host immune response rather than via their antimicrobial properties [93,94].…”

Section: Chronic Rhinosinusitismentioning

confidence: 99%

Long-term macrolide treatment for chronic respiratory disease

2012

View full text Add to dashboard Cite

Long-term macrolide treatment was first shown to alter the natural history of diffuse panbronchiolitis (DPB) in the late 1980s. Since then, macrolides have been demonstrated to exert antiinflammatory and immunomodulatory activity in addition to being antimicrobial. Indeed, their spectrum of action extends to the regulation of leukocyte function and production of inflammatory mediators, control of mucus hypersecretion, resolution of inflammation and modulation of host defence mechanisms. As such, the potential benefit of macrolide antibiotics has been evaluated in a variety of chronic respiratory diseases. The best studied condition is cystic fibrosis, of which there have been six randomised controlled trials showing evidence of benefit. However, most of the studies were limited by small numbers of patients and short follow-up. More recently, landmark studies have demonstrated the efficacy of azithromycin in reducing the risk of acute exacerbations in patients with chronic obstructive pulmonary disease, but the optimal duration and dosing of macrolide treatment remain uncertain.With the exception of patients with DPB and cystic fibrosis, until clear evidence of efficacy is available, the long-term use of macrolides should be limited to highly selected patients after careful evaluation of benefit and harm, or in the context of randomised controlled clinical trials. @ERSpublications Several studies evaluating macrolide antibiotics for the treatment of chronic respiratory diseases are underway

show abstract

“…It is no longer than 5 years since the first studies on these biologic factors were performed in chronic sinusitis (8)(9)(10)(11) and, because of the relationship to eosinophilic inflammation in asthma, also in nasal polyposis (12)(13)(14)(15)(16)(17). This review aims to update these findings, but also to demonstrate the contradictory results and interpretations whieh have resulted from the small database available today.…”

mentioning

confidence: 99%